Coya Therapeutics, Inc.COYAEarnings & Financial Report
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative regulatory T cell (Treg)-based therapies to address unmet medical needs for patients with neurodegenerative, autoimmune, and inflammatory diseases. Its core pipeline includes lead candidates targeting conditions like amyotrophic lateral sclerosis, with primary planned commercial markets across North America and the European Union.
COYA Q4 FY2025 Key Financial Metrics
Revenue
$4.0M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
202768.8%
Coya Therapeutics, Inc. Q4 FY2025 Financial Summary
Coya Therapeutics, Inc. reported revenue of $4.0M (up 202768.8% YoY) for Q4 FY2025, with a net profit of N/A (down 95.8% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $4.0M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Coya Therapeutics, Inc. Quarterly Revenue & Net Profit History
Coya Therapeutics, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $4.0M | +202768.8% | N/A | N/A |
| Q3 FY2025 | $3.6M | — | $-2.1M | -59.4% |
| Q3 FY2024 | $0 | — | $-4.0M | N/A |
| Q2 FY2024 | $3.4M | — | $-2.9M | -84.4% |
Income Statement
| Q2 2024 | Q3 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Revenue | $3.4M | $0 | $3.6M | $4.0M |
| YoY Growth | N/A | N/A | N/A | 202768.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Assets | $39.9M | $35.6M | $32.0M | $50.0M |
| Liabilities | $4.7M | $3.5M | $4.8M | $6.9M |
| Equity | $35.3M | $32.0M | $27.3M | $43.0M |
Cash Flow
| Q2 2024 | Q3 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-4.6M | $-5.5M | $-1.1M | $-10.7M |